|Videos|June 17, 2015
Clinical Trial Design for Immunotherapy
Advertisement
Episodes in this series
Advertisement
Related to this article
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
2
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
3
Five Under 5: Top Oncology Videos for the Week of 9/27
4
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
5